No Data
Investors Don't See Light At End Of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Tunnel And Push Stock Down 33%
The Puma Biotechnology, Inc. (NASDAQ:PBYI) share price has fared very poorly over the last month, falling by a substantial 33%. Instead of being rewarded, shareholders who have already held through
We Think Shareholders Are Less Likely To Approve A Pay Rise For Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO For Now
Key Insights Puma Biotechnology to hold its Annual General Meeting on 18th of June Total pay for CEO Alan Auerbach includes US$877.9k salary Total compensation is similar to the industry average
PUMA Continues Its Biggest Marketing Push With EURO and COPA Spin-Offs
HERZOGENAURACH, Germany--(BUSINESS WIRE)--Global sports company PUMA has launched the second chapter of its first worldwide brand campaign in 10 years "FOREVER. FASTER. - See The Game Like We Do". New
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock
Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
Express News | Puma Biotechnology Presents Phase I/Ib Study On Alisertib For Osimertinib-Resistant EGFR-Mutated Lung Cancer At ASCO 2024